We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Uveitis Gene-Expression Profiling

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00874471
First Posted: April 2, 2009
Last Update Posted: April 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jim Rosenbaum, Oregon Health and Science University
  Purpose

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

  1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
  2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
  3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
  4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.


Condition
Uveitis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Jim Rosenbaum, Oregon Health and Science University:

Primary Outcome Measures:
  • Correlation of blood transcriptome with form of uveitis [ Time Frame: time of office visit for disease evaluation ]

Enrollment: 280
Study Start Date: June 2005
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
sarcoidosis
ankylosing spondylitis
Behcet's disease
toxoplasmosis
herpetic acute retinal necrosis
idiopathic uveitis
ankylosing spondylitis (no uveitis)
sarcoidosis (no uveitis)
Behcet's disease (no uveitis)
normal control

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals suffering from selected subtypes of uveitis, individuals suffering from selected autoimmune disease and healthy individuals.
Criteria

Inclusion Criteria:

  • The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:

    1. ankylosing spondylitis
    2. sarcoidosis
    3. Behçet's disease
    4. toxoplasmosis
    5. herpetic acute retinal necrosis; AND
    6. idiopathic uveitis
  • Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:

    1. ankylosing spondylitis
    2. sarcoidosis; AND
    3. Behçet's disease
  • The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion Criteria:

  • Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00874471


Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239-3098
Sponsors and Collaborators
Oregon Health and Science University
Investigators
Principal Investigator: James Rosenbaum, MD Oregon Health and Science University
  More Information

Responsible Party: Jim Rosenbaum, Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00874471     History of Changes
Other Study ID Numbers: R01EY015858 ( U.S. NIH Grant/Contract )
First Submitted: April 1, 2009
First Posted: April 2, 2009
Last Update Posted: April 9, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Uveitis
Uveal Diseases
Eye Diseases